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Study Design: A case-series study.
Purpose: To assess the long-term clinical and radiographic outcomes after vertebroplasty using calcium phosphate cement (CPC) 
for treatment of osteoporotic vertebral fractures (OVF).
Overview of Literature: Vertebroplasty has become common for the treatment of OVF. However,  few studies have reported 
the clinical application of CPC to vertebroplasty. 
Methods: We reviewed 86 consecutive patients undergoing 99 vertebroplasties using CPC. Following repositioning and cu-
rettage of the pathological soft tissue of the vertebral body (VB),  vertebroplasty using CPC was performed in patients with 
osteoporotic burst fracture and pseudoarthrosis (procedure A). Vertebroplasty was also performed in patients with osteoporotic 
compression fractures (procedure B). Back pain and lower back pain were evaluated using the visual analogue scale (VAS). 
The VB deformity index was measured in a lateral radiograph as the ratio of the VB’s height to its longitudinal diameter. 
Results: The mean age at time of surgery was 77 years old. The mean duration of follow-up was forty-four months. All 
patients reported decreased pain according to the VAS immediately after vertebroplasty,  and pain relief was maintained at 
the last follow-up in all patients without new OVFs. Complete bone union was observed in all cases by six months af-
ter surgery. The mean recovery rate of deformity index was 5.9% in procedure A and 0.02% in procedure B at the final 
follow-up visit.
Conclusions: Vertebroplasty using CPC gave a satisfactory outcome and no delayed complications in elderly patients with 
osteoporotic vertebral fractures at follow-up times of at least two years.
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Introduction
Vertebroplasty, the augmentation of the vertebral body 
(VB) by percutaneous polymethylmethacrylate (PMMA) 
injection, results in good enhancement of VB strength and 
pain relief for osteoporotic vertebral fractures (OVF) [1-
3]. A number of biodegradable bone cement substitutes 
which might be thought of as alternatives for PMMA 
have been developed and biomechanically tested [4,5]; 
however, none were readily available for use in the spine. Copyright Ⓒ 2012 by Korean Society of Spine Surgery
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One of these substitutes, calcium phosphate cement (CPC), 
was developed in 1993; it can be mixed into an injectable 
paste and is self-setting, radiopaque, biocompatible, 
biodegradable, and osteoconductive [6-8]. It tends to 
be resorbed progressively from the outer surface and 
replaced by bone tissue during the normal bone remodeling 
process [9,10]. CPC has been proven to be useful in VB 
augmentation in patients with osteoporosis [9-11] and has 
been available for clinical use in the spine since 2000 [10].
 
In previous clinical studies, percutaneous transpedicular 
vertebroplasty using CPC was found to be a minimally 
invasive procedure that provided pain relief [9,12]. 
However, vertebroplasty using CPC has invoked both 
enthusiasm and controversy, in part because the handling 
characteristics differ from those of PMMA, resulting in 
some correction loss of the VB [9,12,13], and few studies 
have reported the results of a long-term follow-up. The 
object of this prospective study was to assess the clinical 
outcome of vertebroplasty using CPC for OVF after a 
minimum follow-up duration of two years and to discuss 
the technical points of the clinical application of CPC for 
vertebroplasty.
Materials and Methods
We reviewed 106 consecutive patients undergoing 123 
vertebroplasty procedures using CPC between July 2000 
and October 2003. All of the patients were admitted with 
thoracic, thoracolumbar, or lumbar vertebral fractures due 
to osteoporosis. The inclusion criteria included painful OVF 
matched with radiographic findings. In the assessment of 
these patients, the location of osteoporotic vertebral frac-
tures was diagnosed by radiography and magnetic resonance 
imaging. The other inclusion criteria were the presence 
of osteoporosis as diagnosed by radiography and/or bone 
mineral density based on the Clinical Practice Guideline 
of the Japanese Osteoporosis Society [14] and a minimum 
age of sixty years. Exclusionary criteria included pathologic 
fracture due to myeloma/metastasis and osteomyelitis, 
coagulopathy, a neurological deficit related to the fracture, 
and multilevel OVFs over three levels. The human research 
ethics committee at our hospital approved the study, and all 
participants provided written informed content.
We selected two procedures [9]: 1) Following reposition-
ing and curettage of the pathological soft tissues of the VB, 
Fig. 1. Diagrams depicting the steps of the percutaneous vertebroplasty procedure using calcium phosphate 
cement (CPC). (A) Two Jamshidi needles are inserted percutaneously and transpedicularly under fluoroscopic 
guidance. (B) Guide pins (1.5-mm diameter) are inserted through the needles. (C) Two portals are set on the 
bilateral laminae after dilating using the dilators. (D, E) Debridement of the pathologic tissues in the vertebral 
body and reduction are performed using rongeurs, curettes, probes, and a urinary balloon. (F) Finally, CPC in-
jection and filling are performed after injection of the contrast media and washing with saline. 
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vertebroplasty using CPC (Biopex, Pentax, Tokyo, Japan) 
was performed in patients with osteoporotic burst fracture 
and pseudoarthrosis (procedure A) (Figs. 1 and 2). 2) Verte-
broplasty was also performed in patients with osteoporotic 
compression fractures (procedure B). The selection crite-
ria for procedure A included computed tomography (CT) 
scanning evidence of a posterior wall fracture of the VB 
with displacement and bulging of more than 2 mm and/
or presentation more than eight weeks after the time of the 
injury. Those for procedure B included both CT scanning 
evidence of posterior wall fracture of VB with displacement 
and bulging of less than 2 mm, and presentation fewer than 
eight weeks after the time of the injury. 
Procedure A was described in a previous paper [9]. Fig. 
1 illustrates the overall sequence of this procedure. Two 
11-gauge Jamshidi needles (Allegiance Healthcare Corpora-
tion, McGraw Park, IL, USA) are inserted percutaneously 
and transpedicularly after induction of general anesthesia 
(Fig. 1A). Two 1.5-mm-diameter guide pins are inserted 
through the Jamshidi needles (Fig. 1B). Two portals are set 
on the bilateral laminae medial to the transverse process 
after two skin incisions (10 mm) are made, and dilators are 
used along the guide pins for dilation (Fig. 1C). To bond 
CPC to the bone and space in the VB, debridement of the 
pathologic soft tissues in the VB and reduction are per-
formed through the portals using rongeurs, angled curettes, 
Fig. 2. Representative radiographs and computed tomography (CT) findings demonstrating a typical example 
of pseudoarthrosis following osteoporotic compression fracture. (A, B) Preoperative flexion-extension lateral 
radiographs demonstrating significant instability and kyphotic deformity of the vertebral body at T12 and L1. 
(C) A postoperative radiograph obtained immediately after procedure A revealing excellent augmentation of 
the vertebral body and significant correction of the kyphotic deformity of 30° in the Cobb measurement. (D) At 
3 months after surgery, the correction is relatively decreased because the CPC mass was partially broken and 
displaced anteriorly. (E, F) A postoperative CT finding obtained one week after surgery demonstrating the pre-
operative defect filled with calcium phosphate cement at T12 (E) and L1 (F).
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impactors, and probes (Fig. 1D and 1E). A preparation of 
CPC with a powder/liquid ratio of 2.8 to 3.6 is used two 
minutes after mixing [6-11]. After intra-vertebral injec-
tion of the contrast media and washing with saline, CPC 
injection and filling are performed using 8-gauge Jamshidi 
needles and 1-ml syringes (Fig. 1F). All of these techniques 
are performed with the aid of fluoroscopic guidance.
In procedure B, in-situ CPC injection is performed after 
induction of local anesthesia. This procedure was performed 
in the same manner as previously reported for percutaneous 
vertebroplasty using PMMA [2,3]. Two Jamshidi needles 
are inserted percutaneously and transpedicularly with the 
aid of fluoroscopic guidance. The CPC powder/liquid ratio 
is 2.6 to 3.0 [6-11]. Postoperatively, in both groups (pro-
cedure A and B), ambulation was initiated on Day 7 after 
operation when the compressive strength of CPC (Biopex) 
reached its maximum. 
Back pain and lower-back pain were evaluated using 
the visual analogue scale (VAS, 0 to 100 mm) [15] and 
the duration of analgesic medication requirement. The 
evaluation of pain in patients who suffered newly developed 
fractures of other VB was discontinued. Walking ability 
was classified into four grades: grade I, the patient cannot 
walk and needs a wheel chair; grade II, the patient can only 
walk using a walker; grade III, the patient can walk using a 
stick or a crutch; and grade IV, the patient can walk without 
a stick. To evaluate VB deformity, the deformity index was 
measured on a lateral radiograph as the ratio of VB height 
(sum of measurements at anterior, middle, and posterior 
regions) to its longitudinal diameter (Fig. 3) [9,12]. The 
kyphosis rate of the VB was expressed as the percentage of 
VB height at the anterior region to its height at the posterior 
region. Each outcome was obtained before surgery and 
daily up to two weeks (with VAS score), at 1, 2, 3, 6, 12 and 
24 months postoperatively, and at the final follow-up visit.
To evaluate changes from pre- to postoperative status 
in VAS score, the deformity index, and the kyphosis rate 
of the VB, statistical analyses were performed using the 
paired t-test. Variables were corrected for baseline values by 
subtracting the follow-up measurement from the baseline 
value and expressing the difference as a percentage of the 
baseline value. A probability value of less than 0.05 was 
accepted as the level of statistical significance.
Results
Procedure A was applied to forty-one patients with thirty-
eight osteoporotic burst fractures (two at T9, one at T11, ten 
at T-12, seven at L-1, seven at L-2, two at L-3, seven at L-4, 
and two at L-5) and with twelve pseudoarthroses or late col-
lapse (four at T-12, two at L-1, two at L-2, and four at L-4). 
Procedure B was applied to sixty-five patients with osteo-
porotic vertebral compression fractures (one at T-6, two at 
T-8, two at T-9, three at T-10, four at T-11, fifteen at T-12, 
twenty-three at L-1, eight at L-2, eight at L-3, four at L-4, 
and three at L-5). The mean interval from injury to surgery 
in Procedure A was 43.6 days (range, 6 to 270 days), and in 
Procedure B it was 17.7 days (range, 3 to 56 days). 
Eight patients (9.3%) died after less than two years fol-
low-up as a result of causes that were unrelated to the verte-
broplasty, and twelve patients (11.3%) were lost to follow-
up. Thus, eighty-six patients (twenty-two men and sixty-
four women) (99 VBs) had a minimum of two years of 
follow-up. The mean duration of follow-up was 44 months 
(range, 24 to 60 months). The mean age at time of surgery 
was 77 years old (range, 60 to 95 years).
The VAS score could be assessed in 75 patients. The 
patients who underwent procedure A suffered from 
intractable pain preoperatively, which had been unresolved 
by nonoperative care. The mean preoperative VAS was 
87.6 mm (range, 60 to 100 mm). The mean VAS score 
immediately after surgery was decreased to 50 mm (range, 
20 to 80 mm; p < 0.0001). The mean VAS after ambulation 
initiation was 30 mm (range, 10 to 50 mm; p < 0.0001). 
The mean VAS scores were 9.6 mm, 9.5 mm, and 7.4 mm 
at the 6- and 12-month follow-up examinations and at the 
final follow-up visit (range, 24 to 60 months), respectively 
(p < 0.0001). The patients who underwent procedure B also 
Fig. 3. A scheme for evaluating the sagittal-plane correction 
of the vertebral body (VB) deformity on a lateral radiograph 
taken in the neutral decubitus position [10,13,15]. The 
deformity index = (a + c + p)/d; this index analyzes the de-
formity of the VB. The kyphosis rate (%) = 100 × a/p; this 
measures the kyphotic deformity of the VB.38 / ASJ: Vol. 6, No. 1, 2012
suffered from intractable pain preoperatively; the mean 
preoperative VAS score was 85 mm (range, 50 to 100 mm). 
The mean VAS score immediately after surgery decreased 
to 36.8 mm (range, 10 to 70 mm; p < 0.0001). The mean 
VAS after ambulation initiation was 23.3 mm (range, 0 to 
50 mm; p < 0.0001). The mean VAS scores were 5.2 mm, 
3.3 mm, and 3.3 mm at the six and twelve-month follow-
up examination and at the final follow-up visit (range, 24 to 
60 months), respectively (p < 0.0001). The mean VAS score 
immediately after surgery was decreased to 42 mm from 
86.2 mm (p < 0.0001). In all patients without new OVFs, 
pain relief was maintained at the last follow-up. The mean 
duration of analgesic medication requirement in patients 
who underwent procedures A and B were 22.7 ± 85.8 days 
and 14.6 ± 30.5 days, respectively.
Walking ability decreased by more than one grade in 9 of 
86 patients (10.5%) at the 12-month follow-up examination 
as compared with the ability before injury, from grade IV to 
grade III in 2 cases of procedure A and 3 cases of procedure 
B, from grade IV to grade II in one case of procedure A and 
2 cases of procedure B, and from grade III to grade II in 
one case of procedure B. Walking ability was preserved in 
77 patients (89.5%), and it was improved from grade II to 
grade III in 3 cases, from grade I to grade III in one case, 
and from grade I to grade IV in one case. The mean grade 
of walking ability was 3.43 in procedure A and 2.95 in pro-
cedure B before injury, which changed to 3.25 and 2.94, 
respectively, at the 12-month follow-up examination. 
The mean amount of CPC injected into each individual 
was 6.5 ml (range, 2.5 to 10 ml) for procedure A and 3.9 ml 
(range, 1 to 6.5 ml) for procedure B. The mean operative 
times for procedures A and B were 62.1 minutes (range, 32 
to 100 minutes) and 26.4 minutes (range, 15 to 47 minutes), 
respectively. The mean amount of intraoperative blood loss 
in procedure A was 21 g (n = 6; range, 10 to 30 g: It was too 
insignificant to count in the other cases), and the blood loss 
in procedure B was too insignificant to count in all cases.
The mean preoperative VB deformity index was 1.57 in 
procedure A and 1.73 in procedure B, which improved to 
1.75 and 1.88, respectively, just after surgery (p < 0.0001 
and p < 0.0001, respectively). At the final follow-up visit 
(range, 24 to 60 months), the mean deformity index was 1.62 
in procedure A and 1.72 in procedure B (p = 0.084 and p = 
0.6763, respectively). The mean recovery rate of deformity 
index was 5.9% in procedure A and 0.02% in procedure B.
The mean preoperative kyphosis rate of the fractured 
VB was 75.6% in procedure A and 75.3% in procedure B, 
which improved to 88.7% and 86.4%, respectively, just 
after surgery (p < 0.0001 and p < 0.0001, respectively). At 
the final follow-up visit, the mean kyphosis rate was 79.3% 
in procedure A and 76.4% in procedure B (p = 0.1935 and 
p = 0.4446, respectively), and the mean recovery rate was 
10.5% in procedure A and 2.5% in procedure B. Satisfac-
tory bone union was demonstrated on CT or sagittal tomo-
graphic images in all cases until 6 months after surgery. The 
injected CPC gradually tended to disappear and be replaced 
by newly developed bone as demonstrated on CT images 
at 3, 6, 12, 24, and/or 36 months after surgery in all patients 
who underwent this modality (Fig. 4). The degradation of 
the CPC mass was observed only in the interface to the 
Fig. 4. Computed tomography (CT) studies demonstrating an example of osteoporotic burst fracture at L3. A 
preoperative CT (A) demonstrating the fracture line from the anterior to middle column including a posterior 
wall fracture of the vertebral body with displacement and bulging at 30 days after injury. A postoperative CT 
obtained 1 week after procedure B (B), demonstrating the preoperative defect filled with calcium phosphate 
cement. At the 3-years follow-up, the injected calcium phosphate cement is partially absorbed and replaced by 
newly formed bone, and the fragment of fractured posterior wall is remodeled in the spinal canal (C). 
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bone, and the hydroxyapatite mass was preserved in the VB. 
A greater than 10% decrease in the VB deformity index was 
seen at the final examination compared with the value im-
mediately after surgery in 28 of 99 VBs and less than 50% 
for the kyphosis rate at the last follow-up in 8 of 99 VBs.
One patient suffered from temporary respiratory 
insufficiency during the CPC injection in procedure 
B (0.9%). In this patient, there was no evidence of a 
pulmonary embolism induced by CPC on postoperative 
lung CT image and radiograph. There was a small amount 
of CPC leakage into the spinal canal in seven cases (6.6%), 
into the intervertebral disc in seven cases (6.6%), and 
into the paravertebral muscle in one (0.9%); however, 
no patients presented with neurological abnormalities or 
infection or required revision surgery.
Twenty-one newly developed vertebral fractures were 
seen, including eight vertebral fractures at an adjacent level 
(9.3%). Although no pulmonary embolisms were observed, 
a deep venous thrombosis was diagnosed in one patient. 
Two patients suffered from urinary tract infections, and one 
patient suffered with ileus.
Discussion
Vertebroplasty for OVF is a minimally invasive 
procedure and effective for the relief of intractable pain as 
shown in previous studies [2,9]. Although two multicenter, 
randomized-controlled studies showed that improvement in 
pain and pain-related disability associated with osteoporotic 
compression fractures in patients treated with vertebroplasty 
were similar to improvement in a sham operation group, 
they included patients with acute vertebral fractures, which 
might expect to be a good prognosis in a conservative 
treatment [16,17]. In these studies, they only reported the 
short-term clinical outcome up to 6 months after treatment 
and did not perform radiological assessment. In spite of 
these two studies, one controversial study reported that 
kyphoplasty is an effective and safe procedure for treatment 
in patients with acute vertebral fractures compared with 
conservative treatment [18]. These above studies used 
PMMA for both vertebroplasty and kyphoplasty. In this 
present study, we are the first to demonstrate that the clinical 
application of CPC for vertebroplasty is effective and safe 
in a long follow-up period in a minimum or 2 years after 
treatment. We also showed radiological recovery after 
vertebroplasty.
One of the biodegradable bone cement substitutes, CPC, 
can be mixed into an injectable paste like PMMA. In a 
study using cadavers, CPC augmented the vertebral strength 
as compared with intact vertebral bodies at 10 days after 
injection [11]. At present, in the second generation of CPC 
(Biopex-R), the maximum compressive strength is 80 MPa 
in 72 hours after mixing powder with liquid, which is strong 
enough to reinforce the osteoporotic vertebral body. As the 
compressive strength of CPC (80 MPa) is lower than that 
of PMMA (99 MPa) [6-8,19], vertebroplasty using PMMA 
may provide a better radiological result than that using CPC 
for OVF. Although CPC has the same risk associated with 
cement extrusion, we prefer CPC to PMMA especially 
for younger patients with osteoporotic vertebral fractures 
because CPC is more biocompatible, more biodegradable, 
more osteoconductive, and may be safer than PMMA.
Vertebroplasty using CPC invokes controversy, in part 
because of the handling characteristics that differ from 
those of PMMA, including cost, performance, and the long 
hardening time. Because CPC is more difficult to inject 
under high local pressure than PMMA, a bilateral approach 
through the bilateral pedicles and cavity formation of the 
VB before vertebroplasty might be necessary. Although new 
devices and materials for vertebroplasty and kyphoplasty 
Table 1. Incidence of cement leakage
Cement leak (%) Technique, disease Author (year)
37.5 Vertebroplasty-PMMA, malignant tumor Cotten et al. (1996) [21]
65 Vertebroplasty-PMMA, OVF  Cortet et al. (1999) [2] 
40.3 Vertebroplasty-PMMA, OVF  Ryu et al. (2002) [20] 
7.8 Vertebroplasty-CPC, OVF  Nakano et al. (2005) [13]
8.6 Kyphoplasty-PMMA, OVF  Lieberman et al. (2001) [22] 
9 Kyphoplasty-PMMA, OVF, malignant tumor  Ledlie and Renfo (2003) [23] 
8.7 Vertebroplasty-CPC following intravertebral operation  Nakano et al. (2005) [13]
PMMA: Polymethylmethacrylate, OVF: Osteoporotic vertebral fracture, CPC: Calcium phosphate cement.40 / ASJ: Vol. 6, No. 1, 2012
can be developed in the future, for the present, our findings 
in the current study suggest vertebroplasty following 
repositioning and curettage of the pathological soft tissues 
of the VB (procedure A in this study) is one of the best 
effective and safe procedures for the clinical application of 
CPC in the treatment of osteoporotic vertebral fractures, 
including burst type fractures, pseudoarthroses, and late 
collapse . 
Initially, the height of the VB and kyphosis rates 
improved significantly for both treatment groups in this 
study. However, this improvement was lost with the passage 
of time. In our experiences, mixing blood with CPC could 
result in fragmentation of the CPC mass and subsequent 
loss of correction [9]. Control of bleeding from the VB 
during the procedure is important for this reason. In the 
second generation of CPC (Biopex-R), the fragmentation 
incidence of the CPC mass due to mixing with blood is 
decreasing. At least we can speculate that it is important to 
use a larger amount and a higher powder/liquid ratio of the 
injected CPC to achieve good correction. On the other hand, 
we recommend that the injection amount should be kept at 
less than 9 ml for thoraco-lumbar lesions, and the powder/
liquid ratio of CPC (Biopex) should be kept at higher than 
2.7 (more than 3.4 with Biopex-R) because an excessive 
amount and an excessively low powder/liquid ratio of CPC 
may increase the risk of leakage and embolism.
While the incidence of cement leakage following 
vertebroplasty using PMMA is 40% to 65%, that following 
in-situ vertebroplasty using CPC was 7.8% in a previous 
study (Table 1) [2,13,20-23]. A low rate of CPC leakage 
may be due to the patient selection for the two procedures: 
vertebroplasty and vertebroplasty following repositioning 
and curettage of the pathological soft tissues. Regarding new 
vertebral fractures at an adjacent level after vertebroplasty 
and kyphoplasty using PMMA and CPC in the literature, 
the fracture rate in this study using CPC was not high as 
compared with that in vertebroplasty and kyphoplasty using 
PMMA or with the use of conservative treatment, although 
the indication and follow-up periods were different (Table 2) 
[23-28]. While ambulation was initiated at postoperative 7 
days after CPC injection in this study, ambulation could be 
started right after PMMA injection. Although the maximum 
compressive strength is 80 MPa in 72 hours after injection 
of second-generation CPC (Biopex-R), bed rest for over 
3 days may lead to other complications, such as deep vein 
thrombosis and bed sores, in addition to a decrease in the 
patient’s satisfaction. It also requires longer hospitalization 
and is costlier. In addition, CPC itself is more expensive 
than PMMA.
Study limitations include the fact that there were not any 
control groups. Recently, in the prospective cohort study, no 
statistically significant differences were observed between 
the other type of CPC and PMMA-cement in balloon-
kyphoplasty for patients with painful osteoporotic vertebral 
fractures regarding VAS-scores, mobility-scores, or height-
restoration; in addition, no significant difference in the 
occurrence of vertebral follow-up fractures were noted 
between the groups [29]. To compare CPC with PMMA 
Table 2. Subsequent adjacent vertebral fracture after kyphoplasty and vertebroplasty
Fracture rate (%) Follow up (mo) Author (year) 
Untreated OVCF
19.2 12 Lindsay et al. (2001) [24]
12   6 Kasperk et al. (2005) [25]
Vertebroplasty
52 48 Grados et al. (2000) [26]
  8.3 24 Uppin et al. (2003) [27] 
  7.8 24 B: Vertebroplasty-CPC 
Kyphoplasty
6   6 Kasperk et al. (2005) [25]
5.2 12 Ledlie and Rendo (2003) [23]
28 18 Fribourg et al. (2004) [28] 
4.2 24 A: Vertebroplasty-CPC following intravertebral operation 
OVCF: Osteoporotic vertebral compression fracture, CPC: Calcium phosphate cement, A: Procedure A in this study, B: 
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and to compare vertebroplasty with kyphoplasty, it will be 
necessary to perform randomized, controlled trials.
Conclusions
Based on carefully selected patients and only using the 
appropriate amount and powder/liquid ratio of injected 
calcium phosphate cement, vertebroplasty using CPC pre-
vented the VB from late collapse and pseudoarthrosis and 
gave a satisfactory outcome excepting relatively long bed 
rest in patients with OVF after long-term follow-up.
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